CN117653586A - Soluble microneedle and preparation method thereof - Google Patents
Soluble microneedle and preparation method thereof Download PDFInfo
- Publication number
- CN117653586A CN117653586A CN202211064937.6A CN202211064937A CN117653586A CN 117653586 A CN117653586 A CN 117653586A CN 202211064937 A CN202211064937 A CN 202211064937A CN 117653586 A CN117653586 A CN 117653586A
- Authority
- CN
- China
- Prior art keywords
- solution
- microneedle
- soluble
- chitosan
- soluble microneedle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 239000000243 solution Substances 0.000 claims abstract description 79
- 229920001661 Chitosan Polymers 0.000 claims abstract description 46
- 239000007864 aqueous solution Substances 0.000 claims abstract description 43
- 239000000463 material Substances 0.000 claims abstract description 38
- 239000000314 lubricant Substances 0.000 claims abstract description 22
- 238000001035 drying Methods 0.000 claims abstract description 19
- 238000003756 stirring Methods 0.000 claims abstract description 12
- 239000000758 substrate Substances 0.000 claims abstract description 11
- 238000002390 rotary evaporation Methods 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000011248 coating agent Substances 0.000 claims abstract description 6
- 238000000576 coating method Methods 0.000 claims abstract description 6
- 239000012528 membrane Substances 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- -1 polydimethylsiloxane Polymers 0.000 claims description 18
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 17
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 239000011259 mixed solution Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000005266 casting Methods 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims description 4
- 229920002379 silicone rubber Polymers 0.000 claims description 4
- 239000004945 silicone rubber Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 2
- 229940051250 hexylene glycol Drugs 0.000 claims description 2
- 238000007711 solidification Methods 0.000 claims description 2
- 230000008023 solidification Effects 0.000 claims description 2
- 238000010025 steaming Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 13
- 230000010354 integration Effects 0.000 abstract description 4
- 238000012545 processing Methods 0.000 abstract description 4
- 239000002131 composite material Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 10
- 230000008901 benefit Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 4
- 229940043267 rhodamine b Drugs 0.000 description 4
- 238000010586 diagram Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000037368 penetrate the skin Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000007903 penetration ability Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 229940127223 transdermally administered drug Drugs 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0053—Methods for producing microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
The embodiment of the invention discloses a soluble microneedle and a preparation method thereof. The preparation method comprises, for example: dialyzing the cross-linked framework aqueous solution by using a semipermeable membrane to obtain dialysate; adding the dialysate into a lubricant water solution and stirring to obtain a chitosan dilute solution; performing rotary evaporation drying treatment on the chitosan dilute solution to obtain a chitosan concentrated solution; adding the supporting material aqueous solution into the chitosan concentrated solution, stirring and centrifuging to obtain a soluble microneedle base solution; placing the soluble microneedle substrate solution into a microneedle female die, centrifuging and solidifying to obtain an initial soluble microneedle; and coating a backing skeleton solution onto the initial soluble microneedle and curing to obtain the soluble microneedle. The soluble microneedle provided by the embodiment of the invention has good mechanical property and drug release property in water, and the whole preparation process has the characteristics of high integration level, simplicity and rapidness in production, low cost, material saving and flexible processing.
Description
Technical Field
The invention relates to the technical field of medicines. And more particularly, to a soluble microneedle based on a composite material and a method for preparing the same.
Background
At present, transdermal drug delivery technology is a research hotspot in biomedical technology and medical community. However, most transdermally administered drugs have low transmittance due to the natural barrier effect of the stratum corneum, and particularly water-soluble drugs or macromolecular drugs cannot permeate. The micro-needle transdermal administration is a minimally invasive administration mode integrating double advantages of injection administration and the traditional transdermal patch, and the micro-needle can assist the medicine to enter the skin through the stratum corneum, has the length insufficient for touching the subcutaneous pain nerve, and has the advantages of painless minimally invasive, safety and high skin permeability. The microneedles can be generally classified into solid microneedles, coated microneedles, hollow microneedles, and soluble microneedles, according to the mode of administration. Among them, soluble microneedles, which are made of biodegradable polymers, are receiving more and more attention and research, and drugs can be carried by the polymers and released as the polymers dissolve after the microneedles are inserted into the skin. The current preparation process of the soluble microneedle is complex, and in addition, the mechanical emphasis is insufficient due to the small size.
Disclosure of Invention
Aiming at least part of the defects and the defects in the prior art, the embodiment of the invention provides the soluble microneedle based on the composite material and the preparation method thereof, so that the preparation process of the soluble microneedle is simpler, and the prepared soluble microneedle has stronger mechanical strength.
In one aspect, a method for preparing a soluble microneedle provided by an embodiment of the present invention includes: mixing a polydimethylsiloxane curing agent and a prepolymer in a mass ratio of (0.5-3:5-20) in a vacuum environment to obtain a polydimethylsiloxane mixed solution, casting the polydimethylsiloxane mixed solution on a metal microneedle male die, and curing to obtain a microneedle female die; dialyzing the cross-linked skeleton aqueous solution by using a semipermeable membrane to obtain a dialysate, adding the dialysate into a lubricant aqueous solution, stirring to obtain a chitosan dilute solution, and performing rotary evaporation drying treatment on the chitosan dilute solution to obtain a chitosan concentrated solution; wherein the mass percentage range of the cross-linked skeleton in the cross-linked skeleton aqueous solution is 1% -3%, and the mass percentage range of the lubricant in the lubricant aqueous solution is 4% -8%; the temperature range of the rotary steaming drying treatment is 40-70 ℃ and the drying time is 0.5-3h; adding the supporting material aqueous solution into the chitosan concentrated solution, stirring and centrifuging to obtain a soluble microneedle base solution; wherein the mass percentage range of the supporting material in the supporting material aqueous solution is 10% -30%; placing the soluble microneedle substrate solution into the microneedle female die for centrifugation and solidification treatment to obtain an initial soluble microneedle; coating a backing skeleton solution on the initial soluble micro-needle for curing and demolding to obtain the soluble micro-needle; wherein the mass percentage range of the backing skeleton in the backing skeleton solution is 30-50%.
In another aspect, a method for preparing a soluble microneedle provided by an embodiment of the present invention includes: dialyzing the cross-linked framework aqueous solution by using a semipermeable membrane to obtain dialysate; adding the dialysate into a lubricant water solution and stirring to obtain a chitosan dilute solution; performing rotary evaporation drying treatment on the chitosan dilute solution to obtain a chitosan concentrated solution; adding the supporting material aqueous solution into the chitosan concentrated solution, stirring and centrifuging to obtain a soluble microneedle base solution; placing the soluble microneedle substrate solution into a microneedle female die, centrifuging and solidifying to obtain an initial soluble microneedle; and coating a backing skeleton solution on the initial soluble micro-needle and curing to obtain the soluble micro-needle.
In one embodiment of the present invention, the cross-linked skeleton in the aqueous solution of cross-linked skeleton has a mass percentage ranging from 1% to 3%, the lubricant in the aqueous solution of lubricant has a mass percentage ranging from 4% to 8%, and the support material in the aqueous solution of support material has a mass percentage ranging from 10% to 30%.
In one embodiment of the present invention, the spin-evaporating and drying the dilute chitosan solution to obtain a concentrated chitosan solution is specifically: the dilute chitosan solution was stirred and dried under vacuum for 0.5-3 hours, at a pressure of 100Mbar and a temperature in the range of 40-70 ℃.
In one embodiment of the invention, the cross-linked backbone is chitosan; the lubricant is one or more of trehalose, starch and cellulose.
In one embodiment of the present invention, the support material is one or more of carboxymethyl cellulose, hexylene glycol, sorbitol, polyethylene glycol, sodium hyaluronate, polyvinylpyrrolidone, and polyvinyl alcohol.
In one embodiment of the invention, the backing skeleton is one or more of carbomer, methylcellulose, polyvinylpyrrolidone k60, WI-3 tyrosol-b-agent, silicone rubber.
In one embodiment of the present invention, the preparation method further comprises: and mixing a polydimethylsiloxane curing agent and a prepolymer in a mass ratio of (0.5-3:5-20) in a vacuum environment to obtain a polydimethylsiloxane mixed solution, and casting the polydimethylsiloxane mixed solution on a metal microneedle male mold and curing to obtain the microneedle female mold.
In yet another aspect, the embodiment of the present invention provides a soluble microneedle, for example, a soluble microneedle prepared by the preparation method according to any one of the foregoing methods.
In one embodiment of the present invention, the shape of the microneedle is conical, triangular pyramid or polygonal pyramid.
The technical scheme has the following advantages or beneficial effects: the whole preparation flow of the preparation method of the soluble microneedle provided by the embodiment of the invention has the characteristics of high integration level, simplicity and rapidness in production, low cost, material saving and flexible processing, and is suitable for wide popularization and use. In addition, the preparation method comprises the steps of preparing a chitosan dilute solution by preparing a cross-linked framework aqueous solution and a lubricant aqueous solution, performing rotary evaporation drying treatment on the chitosan dilute solution to obtain a chitosan concentrated solution, and adding a support material aqueous solution to obtain a soluble microneedle substrate solution, so that the prepared soluble microneedle has stronger mechanical strength and can penetrate the skin. In addition, it has better drug release effect and great advantage in administration
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for the description of the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
Fig. 1 is a schematic flow chart of a preparation method of a soluble microneedle according to an embodiment of the present invention.
Fig. 2 is a schematic flow chart of another preparation method of a soluble microneedle according to an embodiment of the present invention.
Fig. 3 a-3 c are schematic views of the appearance of a composite soluble microneedle with 8% mass percent of support material, wherein fig. 3a is a schematic view of the appearance of the needle under a 4-fold objective, fig. 3b is a schematic view of the appearance of the needle under a 10-fold objective, and fig. 3c is a schematic view of the overall appearance of the microneedle.
Fig. 4 a-4 c are schematic views of the appearance of a composite soluble microneedle with 20% mass percent of the support material, wherein fig. 4a is a schematic view of the appearance of the needle under a 4-fold objective, fig. 4b is a schematic view of the appearance of the needle under a 10-fold objective, and fig. 4c is a schematic view of the overall appearance of the microneedle.
Fig. 5 is a schematic diagram showing the results of mechanical property test of soluble microneedles prepared by the preparation method provided in the embodiment of the present invention.
Fig. 6a is a schematic view showing the effect of the composite material according to the embodiment of the present invention after the soluble microneedle needles prick the pigskin.
FIG. 6b is a schematic representation of the effect of a pure cross-linked backbone microneedle after needle punching of pigskin.
FIG. 7 is a schematic diagram of the model drug release rate of a pure cross-linked matrix microneedle at different temperatures.
FIG. 8 is a schematic diagram of the model drug release rates of the composite soluble microneedle according to the embodiment of the present invention under different temperature conditions.
Detailed Description
The following description of the embodiments of the present invention will be made clearly and completely with reference to the accompanying drawings, in which it is apparent that the embodiments described are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
It should be noted that the terms "first," "second," and "one end" and the like in the description and the claims of the present invention are used for distinguishing between similar objects and not necessarily for describing a particular sequential or chronological order. It is to be understood that the terms so used are interchangeable under appropriate circumstances such that the embodiments of the invention described herein are capable of operation in sequences other than those illustrated or otherwise described herein. Furthermore, the terms "comprises," "comprising," and "having," and any variations thereof, are intended to cover a non-exclusive inclusion, such that a process, system, article, or apparatus that comprises a list of steps or elements is not necessarily limited to those steps or elements expressly listed but may include other steps or elements not expressly listed or inherent to such process, article, or apparatus.
As shown in fig. 1, an embodiment of the present invention provides a method for preparing a soluble microneedle based on a composite material. The preparation method of the soluble microneedle comprises the following steps:
s10: dialyzing the cross-linked framework aqueous solution by using a semipermeable membrane to obtain dialysate;
s20: adding the dialysate into a lubricant water solution and stirring to obtain a chitosan dilute solution;
s30: performing rotary evaporation drying treatment on the chitosan dilute solution to obtain a chitosan concentrated solution;
s40: adding the supporting material aqueous solution into the chitosan concentrated solution, stirring and centrifuging to obtain a soluble microneedle base solution;
s50: placing the soluble microneedle substrate solution into a microneedle female die, centrifuging and solidifying to obtain an initial soluble microneedle; and
s60: and coating a backing skeleton solution on the initial soluble micro-needle and curing to obtain the soluble micro-needle.
The whole preparation flow of the preparation method provided by the embodiment of the invention has the characteristics of high integration level, simple and quick production, low cost, material saving and flexible processing. In addition, the preparation method comprises the steps of preparing a cross-linked skeleton aqueous solution and a lubricant aqueous solution to obtain a chitosan dilute solution, performing rotary evaporation drying treatment on the chitosan dilute solution to obtain a chitosan concentrated solution, and adding a support material aqueous solution to obtain a soluble microneedle substrate solution, so that the prepared soluble microneedle has good mechanical property and drug release property in water.
Specifically, the mass percentage of the cross-linked framework in the cross-linked framework aqueous solution ranges from 1% to 3%. The mass percentage range of the lubricant in the aqueous solution of the lubricant is 4-8%, and the mass percentage range of the supporting material in the aqueous solution of the supporting material is 10-30%.
Wherein the cross-linked backbone is, for example, chitosan, in particular, e.g. chitosan. The lubricant is one or more of trehalose, starch and cellulose.
The support material is one or more of carboxymethyl cellulose, hexanediol, sorbitol, polyethylene glycol, sodium hyaluronate, polyvinylpyrrolidone and polyvinyl alcohol.
The backing skeleton is one or more of carbomer, methylcellulose, polyvinylpyrrolidone k60, WI-3 tyrosol-bolone, and silicone rubber.
In addition, in step S30, the spin-drying process specifically includes: the method for preparing the chitosan concentrated solution by carrying out spin evaporation drying treatment on the chitosan dilute solution comprises the following steps:
the dilute chitosan solution was stirred and dried under vacuum for 0.5-3 hours, at a pressure of 100Mbar and a temperature in the range of 40-70 ℃.
Further, step S50 specifically includes:
and placing the soluble microneedle substrate solution into the microneedle female die, centrifuging, scraping off redundant soluble microneedle substrate solution on the microneedle female die, and solidifying at the temperature of 40-70 ℃ for 0.5-2 hours to obtain the initial soluble microneedle.
In addition, step S60 specifically includes:
the backing matrix solution is applied to the initial soluble microneedles and cured at a temperature of 40-70 ℃ for 0.5-2 hours, and then the microneedle negative is peeled off to obtain the soluble microneedles.
Furthermore, as shown in fig. 2, the preparation method of the soluble microneedle provided by the embodiment of the invention may further include a preparation step of a female microneedle mould, specifically:
s70: and mixing a polydimethylsiloxane curing agent and a prepolymer in a mass ratio of (0.5-3:5-20) in a vacuum environment to obtain a polydimethylsiloxane mixed solution, and casting the polydimethylsiloxane mixed solution on a metal microneedle male mold and curing to obtain the microneedle female mold. The polydimethylsiloxane curing agent here is an uncrosslinked cured polydimethylsiloxane curing agent, the prepolymer being, for example, SYLGARD184 silicone rubber.
In addition, the mould of the microneedle female mould according to the embodiment of the invention has high transparency, and if the solution for preparing the soluble microneedle has color, after the solution is added into the micropores of the microneedle female mould, whether the solution permeates into the micropores of the mould is convenient to observe. In addition, the microneedle female die can be reused, so that the cost is reduced. After the soluble microneedle is stripped from the microneedle female mold, the microneedle female mold needs to be soaked in purified water for a period of time and then can be used. The female microneedle mould has strong flexibility and can prepare soluble microneedles with different heights according to the needs. The height of the microneedle negative mould is 1000-2000 μm, for example.
In addition, the soluble microneedle prepared by the preparation method of the soluble microneedle provided by the embodiment of the invention is prepared from two composite materials of a crosslinked framework material and a supporting material in a microneedle female die. The soluble microneedles are, for example, conical, triangular pyramid, polygonal pyramid, or other shaped pyramid.
In order to better understand the properties of the soluble microneedles prepared by the preparation method provided in the examples of the present invention, 3 specific test examples will be described below in comparison with pure crosslinked skeletal microneedles.
Test example 1 mechanical Property test of composite-based soluble microneedles
Sufficient mechanical strength is important for the microneedles to pierce the skin to create a tunnel for drug delivery. When preparing the soluble microneedle based on the composite material, as shown in fig. 3 a-3 c, when the mass percentage of the supporting material in the aqueous solution of the supporting material is 8%, the needle surface of the prepared soluble microneedle is flat, and the needle shape is very sharp. When the mass percentage of the supporting material in the supporting material aqueous solution is 10%, the surface of the needle body of the prepared soluble microneedle is very rugged, and the needle tip is also flexible. When the mass percentage of the supporting material in the supporting material aqueous solution is 20%, the needle surface of the soluble microneedle is greatly improved, and the needle tip becomes straight, as shown in fig. 4 a-4 c.
Furthermore, the composite material soluble microneedle based on 20% by mass of the supporting material is shrunken after drying, the length of the needle body is between 500 and 600 μm, and the length of the needle body of the pure cross-linked skeleton microneedle is between 700 and 800 μm. After mechanical property test by using weights, it was found that although the needle body was reduced due to shrinkage after drying due to the soluble microneedle of the composite material, the hardness was better than that of the pure crosslinked skeletal microneedle. As shown in FIG. 5, after weights of 50g and 200g are respectively pressed, the degree of change of the needle body height of the composite material soluble microneedle is obviously smaller than that of the needle body height of the pure cross-linked skeleton microneedle, so that the mechanical property of the soluble microneedle can be improved after the supporting material is added into the soluble microneedle.
Test example 2 microneedle penetration test of soluble microneedle based on composite material
To test the skin penetration ability of the composite dissolvable microneedles of the examples of the present invention, the human skin was replaced with pigskin. As shown in fig. 6a and 6b, both the pure cross-linked skeleton microneedle and the soluble microneedle based on the composite material can be pricked into the pigskin, but the pricked pigskin trace is shallow because the shrinkage of the soluble microneedle based on the composite material is large and the needle body length is short.
Test example 3 drug Release Capacity test of composite-based soluble microneedles
The test method comprises the following steps: rhodamine B is taken as a model drug, after the soluble microneedle is researched to be loaded with the rhodamine B, the rhodamine B is dissolved in an aqueous solution, and the drug release capacity of the pure cross-linked skeleton microneedle and the soluble microneedle based on the composite material is evaluated by measuring the content of the rhodamine B in the aqueous solution. As shown in fig. 7, the pure cross-linked matrix microneedles swelled within the first 15 minutes, and slowly dissolved after about 15 minutes. The pure crosslinked backbone microneedle took about 6 hours to dissolve completely at 37 ℃ and 12 hours at room temperature. As shown in fig. 8, the composite-based soluble microneedle was rapidly dissolved in about 20 minutes, and then slowly dissolved again, and completely dissolved after about 3 hours at 37 ℃ and 4 hours at normal temperature. Thus, the soluble microneedle based on the composite material can dissolve and release the drug in water, and the speed is faster than that of the pure crosslinked skeleton microneedle, and the sustained release drug delivery possibility can be realized in a very uniform and slow speed in the water-soluble process.
In summary, the whole preparation flow of the preparation method of the soluble microneedle provided by the embodiment of the invention has the characteristics of high integration level, simple and quick production, low cost, material saving and flexible processing, and is suitable for wide popularization and application. In addition, the preparation method comprises the steps of preparing a chitosan dilute solution by preparing a cross-linked framework aqueous solution and a lubricant aqueous solution, performing rotary evaporation drying treatment on the chitosan dilute solution to obtain a chitosan concentrated solution, and adding a support material aqueous solution to obtain a soluble microneedle substrate solution, so that the prepared soluble microneedle has stronger mechanical strength and can penetrate the skin. In addition, the medicine has better medicine release performance and great advantage in the administration aspect.
In addition, it should be understood that the foregoing embodiments are merely exemplary illustrations of the present invention, and the technical solutions of the embodiments may be arbitrarily combined and matched without conflict, fixed or contradiction of technical features and without departing from the purpose of the present invention.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present invention, and are not limiting; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims (10)
1. A method of preparing a soluble microneedle comprising:
mixing a polydimethylsiloxane curing agent and a prepolymer in a mass ratio of (0.5-3:5-20) in a vacuum environment to obtain a polydimethylsiloxane mixed solution, casting the polydimethylsiloxane mixed solution on a metal microneedle male die, and curing to obtain a microneedle female die;
dialyzing the cross-linked skeleton aqueous solution by using a semipermeable membrane to obtain a dialysate, adding the dialysate into a lubricant aqueous solution, stirring to obtain a chitosan dilute solution, and performing rotary evaporation drying treatment on the chitosan dilute solution to obtain a chitosan concentrated solution; wherein the mass percentage range of the cross-linked skeleton in the cross-linked skeleton aqueous solution is 1% -3%, and the mass percentage range of the lubricant in the lubricant aqueous solution is 4% -8%; the temperature range of the spin-steaming drying treatment is 40-70, and the drying time is 0.5-3h.
Adding the supporting material aqueous solution into the chitosan concentrated solution, stirring and centrifuging to obtain a soluble microneedle base solution; wherein the mass percentage range of the supporting material in the supporting material aqueous solution is 10% -30%;
placing the soluble microneedle substrate solution into the microneedle female die for centrifugation and solidification treatment to obtain an initial soluble microneedle;
coating a backing skeleton solution on the initial soluble micro-needle to be cured and demoulded to obtain the soluble micro-needle; wherein the mass percentage range of the backing skeleton in the backing skeleton solution is 30-50%.
2. A method of preparing a soluble microneedle comprising:
dialyzing the cross-linked framework aqueous solution by using a semipermeable membrane to obtain dialysate;
adding the dialysate into a lubricant water solution and stirring to obtain a chitosan dilute solution;
performing rotary evaporation drying treatment on the chitosan dilute solution to obtain a chitosan concentrated solution;
adding the supporting material aqueous solution into the chitosan concentrated solution, stirring and centrifuging to obtain a soluble microneedle base solution;
placing the soluble microneedle substrate solution into a microneedle female die, centrifuging and solidifying to obtain an initial soluble microneedle;
and coating a backing skeleton solution on the initial soluble micro-needle and curing to obtain the soluble micro-needle.
3. The method according to claim 2, wherein the cross-linked skeleton in the aqueous solution of the cross-linked skeleton is in a mass percentage range of 1 to 3%, the lubricant in the aqueous solution of the lubricant is in a mass percentage range of 4 to 8%, and the supporting material in the aqueous solution of the supporting material is in a mass percentage range of 10 to 30%.
4. The preparation method according to claim 2, wherein the spin-evaporating and drying treatment of the chitosan dilute solution to obtain a chitosan concentrated solution comprises the following steps:
the dilute chitosan solution was stirred and dried under vacuum for 0.5-3 hours, at a pressure of 100Mbar and a temperature in the range of 40-70 ℃.
5. The method according to claim 2, wherein the crosslinked skeleton is chitosan; the lubricant is one or more of trehalose, starch and cellulose.
6. The method according to claim 2, wherein the support material is one or more of carboxymethyl cellulose, hexylene glycol, sorbitol, polyethylene glycol, sodium hyaluronate, polyvinylpyrrolidone, and polyvinyl alcohol.
7. The method of claim 2, wherein the backing skeleton is one or more of carbomer, methylcellulose, polyvinylpyrrolidone k60, WI-3 tyrosol-b mixture, silicone rubber.
8. The method of manufacturing according to claim 2, further comprising:
and mixing a polydimethylsiloxane curing agent and a prepolymer in a mass ratio of (0.5-3:5-20) in a vacuum environment to obtain a polydimethylsiloxane mixed solution, and casting the polydimethylsiloxane mixed solution on a metal microneedle male mold and curing to obtain the microneedle female mold.
9. A soluble microneedle, characterized in that the soluble microneedle is a soluble microneedle obtained by the preparation method according to any one of claims 1 to 8.
10. The soluble microneedle of claim 9, wherein the microneedle is conical, triangular pyramid or polygonal pyramid in shape.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211064937.6A CN117653586A (en) | 2022-09-01 | 2022-09-01 | Soluble microneedle and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211064937.6A CN117653586A (en) | 2022-09-01 | 2022-09-01 | Soluble microneedle and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117653586A true CN117653586A (en) | 2024-03-08 |
Family
ID=90079534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211064937.6A Pending CN117653586A (en) | 2022-09-01 | 2022-09-01 | Soluble microneedle and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117653586A (en) |
-
2022
- 2022-09-01 CN CN202211064937.6A patent/CN117653586A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109364017B (en) | Rapid separation type soluble microneedle and preparation method thereof | |
CN109045460B (en) | Microneedle patch and preparation method thereof | |
CN108430565B (en) | Microstructure for percutaneous absorption and method for producing same | |
JP5992333B2 (en) | Soluble microneedle | |
CN108785244B (en) | Hydrophobic drug-loaded soluble microneedle and preparation method thereof | |
US10029081B2 (en) | Molding compact, and manufacturing method for transdermal absorption sheet | |
CN107343984B (en) | Method for manufacturing medical micro-needle patch | |
Medhi et al. | Lidocaine-loaded fish scale-nanocellulose biopolymer composite microneedles | |
CN204395040U (en) | Wrap fibrous micro crowning massage paster | |
CN103893018A (en) | Soluble hyaluronic acid micro-needle patch | |
CN108392729A (en) | A kind of cross-linked-hyaluronic acid micropin of grafting drug | |
CN113288882A (en) | Rapid separation microneedle patch and preparation method thereof | |
JP2010069252A (en) | Method for manufacturing transdermal absorption sheet | |
JP2017514646A (en) | Swelled silk fibroin microneedle drug delivery system and method for producing the same | |
CN114917465B (en) | Self-heating microneedle drug-loaded patch and preparation method thereof | |
CN105434332A (en) | Preparation method for water-soluble biological macromolecular microneedle membrane | |
CN115300783A (en) | Double-phase microneedle patch capable of improving drug delivery efficiency and preparation method | |
CN117653586A (en) | Soluble microneedle and preparation method thereof | |
CN116899093A (en) | Novel plaster microneedle patch and preparation method thereof | |
CN113797156B (en) | Hydrogel microneedle and preparation method thereof | |
CN115430031B (en) | Multifunctional beauty microneedle patch and batch preparation method thereof | |
CN111053891A (en) | Polypeptide nanoparticles for treating diabetes, polypeptide nanoparticle microneedles and preparation methods thereof | |
CN110812687A (en) | Preparation method of porous polymer microneedle | |
KR20220141235A (en) | Microneedle array and fabrication method thereof | |
CN212700073U (en) | Compound microneedle patch |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |